TY - JOUR
T1 - Catalytic DNAzymes
T2 - Derivations and functions
AU - Pan, Weihua
AU - Clawson, Gary A.
N1 - Funding Information:
The authors have no significant competing financial interests to disclose. The work was supported in part by grant #CA18591 from the NIH.
PY - 2008/8
Y1 - 2008/8
N2 - Background: Although catalytic RNA enzymes (CRzs) are naturally occurring in many organisms, their DNA counterparts (CDzs) were developed by in vitro selection/evolution from random sequence libraries. Objective: To provide a brief overview of how CDzs have been selected in vitro, and of their properties and functions, as well as their possible future utility. Methods: We concentrated on examples of 'direct' selection of CDzs. Many CDzs have been used in biological settings, for example downregulation of target mRNAs, while many more recent applications use CDzs in biosensor and nanotechnology settings. Conclusions: Although much work has concentrated on using CDzs for regulating gene expression, their potential as nucleic acid medicines has diminished substantially, supplanted by simple antisense oligonucleotides and, more recently, by small interfering RNAs (siRNAs). It seems unlikely that CDzs will have clinical utility. In contrast, they are likely to have significant potential in the sensor/nanotechnology arena.
AB - Background: Although catalytic RNA enzymes (CRzs) are naturally occurring in many organisms, their DNA counterparts (CDzs) were developed by in vitro selection/evolution from random sequence libraries. Objective: To provide a brief overview of how CDzs have been selected in vitro, and of their properties and functions, as well as their possible future utility. Methods: We concentrated on examples of 'direct' selection of CDzs. Many CDzs have been used in biological settings, for example downregulation of target mRNAs, while many more recent applications use CDzs in biosensor and nanotechnology settings. Conclusions: Although much work has concentrated on using CDzs for regulating gene expression, their potential as nucleic acid medicines has diminished substantially, supplanted by simple antisense oligonucleotides and, more recently, by small interfering RNAs (siRNAs). It seems unlikely that CDzs will have clinical utility. In contrast, they are likely to have significant potential in the sensor/nanotechnology arena.
UR - http://www.scopus.com/inward/record.url?scp=47949093606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47949093606&partnerID=8YFLogxK
U2 - 10.1517/14712598.8.8.1071
DO - 10.1517/14712598.8.8.1071
M3 - Review article
C2 - 18613760
AN - SCOPUS:47949093606
SN - 1471-2598
VL - 8
SP - 1071
EP - 1085
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 8
ER -